| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Unrealized gain (loss) on digital assets | -182,887 | - | - | - |
| Realized gain (loss) on foreign currency transactions | -130 | - | - | - |
| Net loss | -1,980,398 | -775,673 | -709,555 | -986,030 |
| Series b convertible preferred stock 8 cumulative dividend | -50,367 | - | - | - |
| Net loss attributable to common stockholders | -2,030,765 | - | - | - |
| Net loss per common share basic | -0.33 | -0.29 | -0.29 | -0.44 |
| Net loss per common share diluted | -0.33 | -0.29 | -0.29 | -0.44 |
| Weighted average common shares outstanding basic | 6,171,195 | 2,720,533 | 2,471,513 | 2,249,290 |
| Weighted average common shares outstanding diluted | 6,171,195 | 2,720,533 | 2,471,513 | 2,249,290 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)